Navigation Links
Repligen Reports Positive Phase 2 Clinical Trial Results of,Secretin for MRI Imaging of the Pancreas

stem. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring contin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/25/2014)... N.C. , Oct. 24, 2014 ... provide Medical Affairs leaders with a forum for ... The consortium has developed a mechanism for creating ... where leaders discuss key findings from the Medical ... has completed the analysis for the first roundtable ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... blood supply to an arm or a leg before heart ... according to a new study. "During heart surgery ... to be able to operate on it. After some time ... produce energy because it doesn,t get oxygen. When we shut ... an arm or a leg, the body prepares for an ...
(Date:10/25/2014)... 2014 (HealthDay News) -- A large influx of international ... to avoid tens of thousands of deaths from the ... predict. Using a specially designed mathematical model, ... outbreak in just one densely populated county of hard-hit ... of Monrovia. The researchers said that if international ...
(Date:10/22/2014)... At a time when the national concussion conversation ... all levels, the UPMC Sports Medicine Concussion Program ... two powerful messages are lost: Concussions can be treated, ... recoveries every day. , In striving to shift the ... UPMC and the Concussion Program are unveiling the online ...
(Date:10/22/2014)... Ann Arbor, MI (PRWEB) October 22, 2014 ... Association of Schools of Allied Health Professions (ASAHP) Conference ... Isabel Founder and CEO will participate in a panel ... Training and Practice. , Isabel Healthcare provides a diagnostic ... assist in improving the diagnosis skills of students and ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... Study highlights:, -- Drug-eluting stents showed improved ... -- No excess adverse events were found ... Nov. 11 Drug-eluting stents,reduced the risk of ... with bare-metal stents in the largest observational comparison,researchers ...
... ORLEANS, Nov. 11 A veteran medical,correspondent ... Howard L.,Lewis Achievement Award for excellence in ... of Freemont, Calif., was honored for "his ... economic,political, ethical and cultural implications of cardiovascular ...
... new technique to study genetic changes that can lead to ... of Nottingham has received 15,000 from the charity Breast Cancer ... by the country,s top breast cancer experts in a recent ... identify the many undiscovered genes thought to be involved in ...
... University of Exeter have found that a walk of ... of exercise in helping people manage dependencies on nicotine ... the first time, newly-published research shows that the same ... days of abstinence, 25 regular chocolate eaters were asked ...
... Unwavering Corporate and Employee Commitment to CourionCares,Philanthropy Program ... Mass., Nov. 11 Courion(R) Corporation,leaders in access ... corporate citizenship program, has raised more,than $100,000 in ... years.,Courion,s eighth annual charity auction held on Friday, ...
... Nov. 11 Misonix, Inc.,(Nasdaq: MSON ), a ... in Europe is used for the ablation of ... announced plans to,release first quarter fiscal year 2009 ... A. McManus, President and Chief,Executive Officer and Richard ...
Cached Medicine News:Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 2Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 3Health News:Drug-Eluting Stents Beat Bare Metal Stents in Diabetics 4Health News:New technique to study the genetics of breast cancer 2Health News:Brisk walk could help chocoholics stop snacking 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 2Health News:Courion Exceeds $100,000 Charitable Giving Milestone with Eighth Annual Employee Fundraiser 3Health News:Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern 2
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
Medicine Products: